C4 Therapeutics Inc (CCCC)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.06-3.77%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge C4 Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	4.67M
EPS	—	-0.272
Annual ending 2026-12-31
Revenue	—	26.42M
EPS	—	-0.851
Annual ending 2027-12-31
Revenue	—	22.28M
EPS	—	-0.944

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Earnings improvement	A supporting condition in C4 Therapeutics Inc's published investment case. The stated target is EPS loss improves by at least 10% year over year.	Improving	EPS loss worsens or fails to improve by 10% in FY27	Diluted EPS: $-0.18 per share FY2026-Q2; GAAP. Published target: EPS loss improves by at least 10% year over year. Target and observation units differ. Source published Aug 11, 2026-0.18 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0cc03b6c-0168-4531-ab97-2fead0099dd8. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Fund operations through 2028	It aims to fund operations through 2028.	Intact	Cash reserves fall below levels needed to fund operations through 2028	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue trend	A primary condition in C4 Therapeutics Inc's published investment case. The stated target is Revenue decline less than -10% next year.	Improving	Revenue declines more than 10% in FY27	Revenue: $6.641M FY2026-Q2; GAAP. Published target: Revenue decline less than -10% next year. Target and observation units differ. Source published Aug 11, 20266,641,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0cc03b6c-0168-4531-ab97-2fead0099dd8. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Strategic partnership with Roche	C4 Therapeutics has a strong partnership with Roche.	Intact	Partnership with Roche ends or fails to advance drug candidates	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.94

Unavailable → $-0.94 · observed estimates

FY2027 revenueUnavailable

$0.02B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$19,140,000	4 / 5
2026-07-25	Unavailable	$19,140,000	4 / 5
2026-07-26	Unavailable	$19,140,000	4 / 5
2026-07-27	Unavailable	$19,140,000	4 / 5
2026-07-28	Unavailable	$19,140,000	4 / 5
2026-07-29	Unavailable	$19,140,000	4 / 5
2026-07-30	Unavailable	Unavailable	4 / 3
2026-07-31	Unavailable	Unavailable	4 / 3
2026-08-01	Unavailable	Unavailable	4 / 3
2026-08-02	Unavailable	$19,140,000	4 / 5
2026-08-03	Unavailable	Unavailable	4 / 3
2026-08-04	Unavailable	Unavailable	4 / 3
2026-08-05	Unavailable	Unavailable	4 / 3
2026-08-06	Unavailable	Unavailable	4 / 3
2026-08-07	Unavailable	Unavailable	4 / 3
2026-08-08	Unavailable	Unavailable	4 / 3
2026-08-09	Unavailable	Unavailable	4 / 3
2026-08-10	Unavailable	Unavailable	4 / 3
2026-08-11	Unavailable	Unavailable	4 / 3
2026-08-12	Unavailable	Unavailable	4 / 3
2026-08-13	Unavailable	Unavailable	4 / 3
2026-08-14	Unavailable	Unavailable	4 / 3
2026-08-15	Unavailable	Unavailable	4 / 3
2026-08-16	Unavailable	Unavailable	4 / 3
2026-08-17	Unavailable	Unavailable	4 / 3
2026-08-18	Unavailable	Unavailable	4 / 3
2026-08-19	Unavailable	Unavailable	4 / 3
2026-08-20	Unavailable	Unavailable	4 / 3
2026-08-21	Unavailable	Unavailable	4 / 3
2026-08-22	Unavailable	Unavailable	4 / 3
2026-08-23	Unavailable	Unavailable	4 / 3
2026-08-24	Unavailable	Unavailable	4 / 3
2026-08-25	Unavailable	Unavailable	4 / 3
2026-08-26	Unavailable	Unavailable	4 / 3
2026-08-27	Unavailable	Unavailable	4 / 3
2026-08-28	Unavailable	Unavailable	4 / 3
2026-08-29	Unavailable	Unavailable	4 / 3
2026-08-30	Unavailable	Unavailable	4 / 3
2026-08-31	Unavailable	Unavailable	4 / 3
2026-09-01	Unavailable	Unavailable	4 / 3
2026-09-02	Unavailable	Unavailable	4 / 3
2026-09-03	Unavailable	Unavailable	4 / 3
2026-09-04	Unavailable	Unavailable	4 / 3
2026-09-05	Unavailable	Unavailable	4 / 3
2026-09-06	Unavailable	Unavailable	4 / 3
2026-09-07	Unavailable	Unavailable	4 / 3
2026-09-08	Unavailable	Unavailable	4 / 3
2026-09-09	Unavailable	Unavailable	4 / 3
2026-09-10	Unavailable	Unavailable	4 / 3
2026-09-11	Unavailable	Unavailable	4 / 3
2026-09-12	Unavailable	Unavailable	4 / 3
2026-09-13	Unavailable	Unavailable	4 / 3
2026-09-14	Unavailable	Unavailable	4 / 3
2026-09-15	Unavailable	Unavailable	4 / 3
2026-09-16	Unavailable	Unavailable	4 / 3
2026-09-17	Unavailable	Unavailable	4 / 3
2026-09-18	Unavailable	Unavailable	4 / 3
2026-09-19	Unavailable	Unavailable	4 / 3
2026-09-20	Unavailable	Unavailable	4 / 3
2026-09-21	Unavailable	Unavailable	4 / 3
2026-09-22	Unavailable	Unavailable	4 / 3
2026-09-23	Unavailable	Unavailable	4 / 3
2026-09-24	Unavailable	Unavailable	4 / 3
2026-09-25	Unavailable	Unavailable	4 / 3
2026-09-26	Unavailable	Unavailable	4 / 3
2026-09-27	Unavailable	Unavailable	4 / 3
2026-09-28	Unavailable	Unavailable	4 / 3
2026-09-29	Unavailable	Unavailable	4 / 3
2026-09-30	Unavailable	Unavailable	4 / 3
2026-10-01	Unavailable	Unavailable	4 / 3
2026-10-02	Unavailable	Unavailable	4 / 3
2026-10-03	Unavailable	Unavailable	4 / 3
2026-10-04	Unavailable	Unavailable	4 / 3
2026-10-05	Unavailable	Unavailable	4 / 3
2026-10-06	Unavailable	Unavailable	4 / 3
2026-10-07	Unavailable	Unavailable	4 / 3
2026-10-08	Unavailable	Unavailable	4 / 3
2026-10-09	Unavailable	Unavailable	4 / 3
2026-10-10	Unavailable	Unavailable	4 / 3
2026-10-11	$-0.94	Unavailable	5 / 4
2026-10-12	$-0.94	Unavailable	5 / 4
2026-10-13	$-0.94	Unavailable	5 / 4
2026-10-14	$-0.94	Unavailable	5 / 4
2026-10-15	$-0.94	Unavailable	5 / 4
2026-10-16	$-0.94	Unavailable	5 / 4
2026-10-17	$-0.94	Unavailable	5 / 4
2026-10-18	$-0.94	Unavailable	5 / 4
2026-10-19	$-0.94	Unavailable	5 / 4
2026-10-20	$-0.94	Unavailable	5 / 4
2026-10-21	$-0.94	Unavailable	5 / 4
2026-10-22	$-0.94	Unavailable	5 / 4
2026-10-23	$-0.94	Unavailable	5 / 4
2026-10-24	$-0.94	Unavailable	5 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	8	0	0
2026-06-01	8	0	0
2026-07-01	8	0	0
2026-08-01	7	0	0
2026-09-01	7	0	0
2026-10-01	8	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Earnings improvementDiluted EPS: $-0.18 per share
Fund operations through 2028Direct metric needs a verified mapping
Revenue trendRevenue: $6.641M
Strategic partnership with RocheDirect metric needs a verified mapping

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.0%Typical daily move · historical

Downside history

-44.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

C4 Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative growth, driven by clinical development and partnerships rather than current profits. The long-term thesis is intact this week, with management priorities on track, but elevated risk and medium confidence temper that view.

What's priced into C4 Therapeutics Inc

Valuation is stretched, with a 1.25 premium versus peers and expectations already leaning ahead of fundamentals. The expectations gap is 0.17, and no fragility gates are triggered, but the business remains loss-making.

What the fundamentals likely do

Near term, the earnings record includes two recent beats, while the next report carries risk in a high-miss-rate industry where peers have missed lately. Over the multi-year view, cemsidomide trials and the Roche collaboration are progressing, and management says cash can fund operations through the end of 2028; litigation filed in September adds a risk whose details are not provided here.

What C4 Therapeutics Inc hinges on

The multi-year thesis depends on clinical progress, including cemsidomide enrollment and data milestones expected in 2027, and on continued execution of the Roche partnership. Near-term, a guidance cut or worsening jobs data could weigh on the business context, while strong results and guidance from healthcare peers could support sector momentum.